Mayflower Financial Advisors LLC Has $1.06 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Mayflower Financial Advisors LLC boosted its position in Stryker Co. (NYSE:SYK) by 2.9% in the 2nd quarter, HoldingsChannel reports. The firm owned 3,108 shares of the medical technology company’s stock after acquiring an additional 88 shares during the period. Mayflower Financial Advisors LLC’s holdings in Stryker were worth $1,057,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Aspen Investment Management Inc lifted its position in shares of Stryker by 0.7% in the first quarter. Aspen Investment Management Inc now owns 4,368 shares of the medical technology company’s stock valued at $1,563,000 after buying an additional 31 shares during the last quarter. Harbor Investment Advisory LLC boosted its position in Stryker by 0.4% during the first quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock worth $2,499,000 after purchasing an additional 31 shares during the period. Proficio Capital Partners LLC increased its holdings in shares of Stryker by 2.4% in the first quarter. Proficio Capital Partners LLC now owns 1,418 shares of the medical technology company’s stock valued at $507,000 after purchasing an additional 33 shares during the last quarter. Versant Capital Management Inc raised its position in shares of Stryker by 4.0% in the second quarter. Versant Capital Management Inc now owns 864 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 33 shares during the period. Finally, Stanley Laman Group Ltd. lifted its stake in shares of Stryker by 4.6% during the 2nd quarter. Stanley Laman Group Ltd. now owns 752 shares of the medical technology company’s stock worth $256,000 after buying an additional 33 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SYK shares. Royal Bank of Canada reissued an “outperform” rating and issued a $386.00 price target on shares of Stryker in a report on Wednesday, July 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. The Goldman Sachs Group assumed coverage on Stryker in a report on Thursday, May 30th. They issued a “neutral” rating and a $372.00 price objective on the stock. Stifel Nicolaus dropped their target price on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Barclays upped their price target on shares of Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $373.84.

Insider Activity

In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now owns 2,852 shares in the company, valued at approximately $949,716. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Viju Menon sold 600 shares of Stryker stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the transaction, the chief financial officer now owns 2,852 shares of the company’s stock, valued at $949,716. The disclosure for this sale can be found here. In the last ninety days, insiders sold 210,600 shares of company stock worth $68,330,400. Insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of SYK stock traded down $0.97 on Thursday, hitting $359.33. 83,166 shares of the company’s stock were exchanged, compared to its average volume of 1,290,723. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $364.36. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. The company has a 50 day moving average of $338.34 and a 200 day moving average of $341.80. The stock has a market cap of $136.89 billion, a P/E ratio of 41.13, a price-to-earnings-growth ratio of 2.78 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. The firm had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.54 earnings per share. On average, equities research analysts predict that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.